Printer Friendly

DNX SUBSIDIARY INTRODUCES FIRST ANIMAL MODEL FOR ATHEROSCLEROSIS AND CORONARY HEART DISEASE

 PRINCETON, N.J., Dec. 13 /PRNewswire/ -- DNX Corporation (NASDAQ: DNXX) today announced its wholly owned subsidiary, Pharmakon Research International, Inc., has introduced the world's first drug testing service utilizing a genetically engineered animal model expressing a key human protein for atherosclerosis and coronary heart disease. This new mouse model, Biodigm-CETP, expresses the human plasma enzyme, cholesterol ester transfer protein (CETP), that is believed to accelerate coronary heart disease in humans. Using this model, Pharmakon is offering pharmacology services to quickly and efficiently identify compounds that inhibit this human protein which will assist pharmaceutical companies in the development of novel treatments against heart disease, the single largest cause of death in the developed world. A major pharmaceutical company has already signed a contract for testing services utilizing Biodigm-CETP.
 "A significant demand exists for animal models for atherosclerosis as most pharmaceutical and biotechnology companies are testing treatments for this disease; Pharmakon's unique mouse models may open the door to designing exactly these types of pharmaceutical agents," said Paul J. Schmitt, President and CEO of DNX. "Currently, all testing of such compounds is primarily done in vitro or in an animal model lacking critical human processes. Yet with Biodigm-CETP, analysis of compounds is moved out of the test tube as Pharmakon can now identify for clients how compounds perform in a whole animal model genetically engineered to mimic human lipoprotein metabolism. This development not only marks a great step forward in the battle against heart disease, it provides a competitive advantage for clients of Pharmakon who are seeking to develop drugs to treat atherosclerosis."
 CETP is thought to accelerate heart disease by transferring cholesterol from high density lipoprotein (HDL), the "good" cholesterol carrier, to low density lipoprotein (LDL), the "bad" cholesterol that accumulates on the walls of arteries and obstructs blood flow. In the Biodigm-CETP, high levels of CETP result in a lipoprotein distribution more similar to humans prone to atherosclerosis -- a dramatic decrease in the level of serum HDL cholesterol and an increase in VLDL and LDL cholesterol. Thus, these genetically engineered mice provide a valuable tool in studying and designing agents to inhibit human CETP and consequently elevate HDL, a strategy that may prevent or reverse atherosclerosis.
 The Biodigm-CETP, Pharmakon's second transgenic animal model, is a new addition to the preclinical testing services offered by Pharmakon worldwide to the pharmaceutical and biotech industries. Biodigms(R), or DNX's proprietary transgenic mice for drug testing, are produced by microinjecting purified DNA fragments with the gene of interest into the pronucleus of fertilized eggs. Pharmakon is the exclusive licensee of DNX's patent covering the basic method of making transgenic animals through DNX microinjection, U.S. Patent No. 4,873,191. DNX and Pharmakon are currently developing a pipeline of proprietary transgenic models to evaluate drug therapies for diabetes, heart disease, Alzheimer's disease, emphysema and inflammatory conditions for inclusion in Pharmakon's pharmacological testing services.
 Pharmakon Research International, Inc. is a full service preclinical research testing laboratory with facilities in Waverly, Pennsylvania and Lyon, France. Founded in 1969, the company offers pharmacology, immunology, toxicology, and pharmacokinetic testing services to a broad client base, including major pharmaceutical, chemical and biotechnology companies in the United States, Europe and Japan.
 DNX Corporation is a leader in the research and development of therapeutic products and biological testing services based on transgenic animal technology. Biological testing services employing Biodigm(R) animal models will be marketed through Pharmakon Research International.
 -0- 12/13/93
 /CONTACT: Paul J. Schmitt, president and CEO of DNX, 609-520-0300 or Vincent B. Ciofalo, Ph.D., vice president-preclinical sciences of Pharmakon, 717-586-2411 or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-696-4455 ext. 202/
 (DNXX)


CO: DNX Corporation; Pharmakon Research International, Inc. ST: New Jersey IN: MTC SU: PDT

LG -- NY020 -- 3005 12/13/93 08:32 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 13, 1993
Words:631
Previous Article:APPLE LAUNCHES NEW VERSION OF HYPERCARD, PROVIDING SIGNIFICANT FLEXIBILITY, POWER AND CUSTOMIZATION ENHANCEMENTS
Next Article:LADY LUCK BILOXI SCHEDULED FOR DEC. 13 OPENING
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters